Terumo Pharmaceutical Solutions wins 2019 Asia-Pacific Industry Award
Accepting the award on behalf of Terumo, from left; Ashit Sikka, Director, Terumo Pharmaceutical Solutions India.
TOKYO, JAPAN and LEUVEN, BELGIUM – February 28th 2019 – Tokyo-based Terumo Corporation (TSE: 4543) has today announced that Terumo Pharmaceutical Solutions has been awarded the Asia-Pacific Bioprocessing Excellence Award 2019 on February 27th at the 6th Biologics Manufacturing Asia & 3rd Bio logistics World Asia 2019 conference awards night held in Singapore.
Terumo Pharmaceutical Solutions was nominated in the category, ‘Best Bioprocessing Supplier Award: Formula t ion & Fill- Finish’ and competed with several other established companies in the industry.
Ashit Sikka, Director, Terumo Pharmaceutical Solutions, India accepted this award on the night on behalf of Terumo.
“For the second year running, Terumo Pharmaceutical Solutions has received this esteemed award in recognition of solution providers with platform technologies that have helped achieve astounding growth in the bio manufacturing space”, said Tetsuya Kumei President, Terumo Pharmaceutical Solutions.
“The success we had with winning this award last year has been reiterated, a great start to 2019 for Terumo Pharmaceutical Solutions! We are very proud that the interest in our PLAJEX™ platform continues and as always we are ready to support our customer’s future requirements”, added Marco Chiadò Piat, Sr. Vice President, Terumo Pharmaceutical Solutions.
The Asia-Pacific Bioprocessing Excellence Award organized by IMAPAC, seeks to give recognition to exceptional biopr ocessing experts, organizations and technologies that facilitate biomanufacturing excellence at enhanced speed, r educed cost and superior quality. Featuring top bioprocessing and biomanufacturing leaders in the industry, along with the latest advances in technologies and best practices in manufacturing, the Asia-Pacific Bioprocessing Excellence Awards applaud extraordinary leaders & trend-setters of today, and inspire innovators of tomorrow.
An esteemed panel of expert judges and the Biologics Manufacturing Asia committee shortlisted the nominees that have proven to be outstanding in their respective categories. They include key opinion leaders with more than 20 years of experience, Process Development Vice Presidents and Directors, Heads of Manufacturing and bioprocessing from all the key players in both Asia and on a global level.
About Terumo Pharmaceutical Solutions
Terumo Pharmaceutical Solutions has been crafting drug delivery devices for generations. Our unique skillset is based on the utmost care – for our industry, our customers and the patients whose quality of life depends on the highest level of healthcare.
Our business relationships are founded on precision, a strong work ethic and open dialogue. We pride ourselves on understanding your needs, anticipating new trends and maintaining constant dialogue with the pharmaceutical industry.
With almost 100 years of experience, we offer a full portfolio of scientific expertise and industry know-how. Our skills range from product design and development to logistics, regulatory affairs, clinical affairs and numerous business processes. Above all, we listen!
Just like our products, our partnerships are Carefully Crafted to benefit everyone.
Terumo Pharmaceutical Solutions
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with over US$5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the health care market and by responding to the needs of health care providers and the people they serve. Terumo Corporation shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.